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Sirtuins (SIRTs) are nicotinamide adenine dinucleotide (NAD+)-dependent protein deacetylases, which regulate important
biological processes ranging from apoptosis, age-associated pathophysiologies, adipocyte and muscle differentiation, and energy
expenditure to gluconeogenesis. Very recently, sirtuin 5 (SIRT5) has received considerable attention due to that it was found to
have weak deacetylase activity but strong desuccinylase, demalonylase and deglutarylase activities, and it was also found to be
associated with several human diseases such as cancer, Alzheimer’s disease, and Parkinson’s disease. In this review, we for the
first time summarized the structure characteristics, known peptide and small-molecule inhibitors of SIRT5, extracted some clues
from current available information and introduced some feasible, practical in silico methods, which might be useful in further
efforts to develop new SIRT5 inhibitors.
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INTRODUCTION
Histone deacetylases (HDACs) are a type of enzymes that
remove acetyl groups from ɛ-N-acetyl-lysine amino groups
on histones and various non-histone proteins. To date,
four classes of histone deacetylases have been identified in
humans (Figure 1) (Hirschey, 2011; Jing and Lin, 2015).
Class I, II, and IV HDACs are zinc2+-dependent deacety-
lases, while class III is nicotinamide adenine dinucleotide
(NAD+)-dependent deacetylases. NAD+-dependent deacety-
lases are also termed sirtuins (SIRTs) due to their homology
to the yeast silent information regulator 2 (SIR2). There
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are seven homologues of sirtuins in human, SIRT1 through
SIRT7. SIRT1-3 have been well studied for decades (Bell
and Guarente, 2011; Donmez and Outeiro, 2013; Mellini et
al., 2015), whereas SIRT4-7 have received relatively little
attention until recently. SIRT5 has become an active topic of
research towards its biological and physiological functions
(Du et al., 2011; Nishida et al., 2015; Polletta et al., 2015; Tan
et al., 2014). Several studies have demonstrated that SIRT5
actually has relatively weak deacetylase activity comparing
with other sirtuins. In contrast, SIRT5 has robust desuc-
cinylation, demalonylation and deglutarylation activities in
vitro and in vivo, ∼1,000-fold higher catalytic efficiency than
deacetylation activity (Roessler et al., 2015). Many studies
also revealed that SIRT5 plays crucial roles in the regulation
of  ammonia detoxification (Nakagawa et al., 2009;  Polletta
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Figure 1   Phylogenetic tree of human HDAC family based on the similarity
of their amino acid sequences. The HDAC family consists of four classes
(Class I, II, III, and IV, shown in different colors). Class I, II, and IV HDACs
are zinc2+-dependent deacetylases, while class III HDACs are nicotinamide
adenine dinucleotide (NAD+)-dependent deacetylases, called sirtuins.
et al., 2015), fatty acid oxidation (Park et al., 2013; Zhang
et al., 2015), cellular respiration (Li et al., 2015a; Park et
al., 2013), ketone body formation (Rardin et al., 2013),
and reactive oxygen species (ROS) management (Lin et
al., 2013), and disregulation or uncontrolled activation of
SIRT5 can cause several human diseases, for instance cancer,
Alzheimer’s disease, and Parkinson’s disease (Kumar and
Lombard, 2015; Lai et al., 2013; Liu et al., 2015; Lu et al.,
2014; Parihar et al., 2015).
Currently, the biological functions and therapeutic possibil-
ities of SIRT5 have been well documented (Du et al., 2011;
Nakagawa et al., 2009; Rardin et al., 2013; Yang et al., 2015).
In this review, we present a summary of characteristics of
SIRT5 structure and inhibitors, and more specifically extract
some clues from current available information and suggest
some useful methods for the design of new SIRT5 inhibitors,
which were expected to be helpful for developing new SIRT5
inhibitors for the treatment of related diseases.
STRUCTURE CHARACTERISTICS OF SIRT5
Several high-resolution crystal structures of SIRT5 have
been reported recently (Du et al., 2011; Roessler et al., 2014;
Schuetz et al., 2007; Szczepankiewicz et al., 2012; Zhou et
al., 2012), which provide valuable clues for the bio-func-
tional mechanism research as well as inhibitor design. From
available crystal structures, we can see that SIRT5 consists
of 14 α helices and 9 β strands, which organized two main
domains: zinc2+-binding domain and Rossmann fold domain
(Figure 2). The zinc2+-binding domain contains a small,
three-stranded antiparallel β sheet (β4, β5, and β6) and five
small α helices (α3, α4, α5, α8, and α9). The zinc ion, which
is coordinated to four cysteine amino residues (including
Cys166, Cys169, Cys207, and Cys212), is the key factor to
keep the three-stranded antiparallel β sheet stable (Figure 2).
The Rossmann fold domain consists of 6 parallel β strands
(β1,  β2,  β3,  β7,  β8 and β9) that form a β sheet center, and
Figure 2   The overall structure of SIRT5.
9 helices (α1, α2, α6, α7, α10, α11, α12, α13 and α14) that sur-
round the β sheet center. The cleft between these two domains
is connected by several loops, which actually forms the cat-
alytic site, including substrate binding site and NAD+binding
site (Figure 2). The loop S, which connects the strand β6 of
the zinc binding domain and the helix α10 of Rossmann fold
domain, is very important for substrate binding. The loop N,
which connects the helix α3 of the zinc2+binding domain and
the α2 helix of the Rossmann fold domain, is important for
NAD+ binding (Figure 2).
By comparing crystal structures of SIRT5 with other sirtu-
ins including SIRT1 (Davenport et al., 2014), SIRT2 (Moniot
et al., 2013), SIRT3 (Jin et al., 2009), and SIRT6 (Pan et al.,
2011), SIRT5 was observed to have a similar overall domain
organization and fold to the structures of SIRT1, SIRT2, and
SIRT3 (Figure 3A), but a different domain fold with SIRT6
especially in zinc2+binding domain and catalytic site (Figure
3B). As shown in Figure 3A, the catalytic sites of SIRT5,
SIRT1, SIRT2, and SIRT3 superimpose very closely, and the
residues around the catalytic site are relatively conserved. For
example, the residues Phe223, Leu227, and Val254 in SIRT5
can be found at the corresponding position in SIRT1, SIRT2,
and SIRT3 (Figure 3A). These three hydrophobic residues
form a small triangle and define the entrance for the acyl-ly-
sine group of the substrate. Especially, Phe223 seems to be
a gate keeper, which can block big motifs enter the substrate
binding site and make way for kind of linear residues such as
lysine,  hence dramatically maintaining  the  substrate selec-
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Figure 3   Bioinformatics analyses revealed that SIRT5 has a similar overall domain organization and fold to SIRT1, SIRT2, and SIRT3, but different to SIRT6
especially in zinc-binding domain and catalytic site. A, Comparative analysis of SIRT5 with SIRT1, SIRT2, and SIRT3. The catalytic sites of these sirtuins are
highlighted in yellow. B, Comparing SIRT5 with SIRT6. SIRT5 is shown in yellow, and SIRT6 is highlighted in blue.
tivity. Another important residue Phe70 is also highly con-
served within sirtuin family (Figure 3A). Phe70 was found to
have two different orientations, like a switch residue. When
the benzene ring of Phe70 interacts with the N-ribose ring via
pi-hydrophobic interactions, Phe70 can stabilize the NAD+or
intermediate, but whilst Phe70 is perpendicular to the ribosyl
ring of NAD+, it seems to favor nicotinamide escape. There
also exist many other conserved residues in sirtuin members
(Figure 3A), which make them possess similar biological
functions. In contrast, an obvious difference between the
domain folds of SIRT5 and SIRT6 was observed (Figure 3B);
SIRT6 does not have small α helices in the zinc2+-binding
domain, which is the conserved structure characteristic for
SIRT1, SIRT2, SIRT3 and SIRT5 (Figure 3A). Besides,
SIRT6 possesses a specific loop X located outside of the
binding site leading to a different active site compared with
SIRT5, which is an important factor contributing to its
specific substrate profile (Figure 3B).
Structural differences between sirtuins can be observed in
the variable amino- and carboxy-terminal extensions (Figure
3A), where they may regulate their subcellular localizations
and catalytic activities, and keep their own specific biological
and physiological functions. Even though in core catalytic
domain, SIRT5 possesses its own specific residues. For
example, the two non-hydrophobic residues Tyr102 and
Arg105, located in the deep end of substrate binding pocket,
are exclusive to SIRT5 (Figure 3A), which are likely to
specifically recognize negatively charged acyl-lysine groups
(i.e. succinyl, demalonyl, and glutaryl). SIRT5 has a small
residue Ala86 (Phenylalanine residue is in the corresponding
position to SIRT1, SIRT2, and SIRT3, see Figure 3A), which
make SIRT5 harbor a larger acyl-lysine binding pocket than
other sirtuins. Due to these specific structural characteristics,
SIRT5 is the only sirtuin member to date demonstrated to
have efficient demalonylase and desuccinylase activity (Du
et al., 2011).
To further understand how substrate and NAD+ bind and
the specificity of SIRT5, one crystal structure reported re-
cently by Du et al. (PDB code: 3RIY) was taken for example
(Du et al., 2011). This is a ternary crystal structure, in which
co-factor NAD+ and succinyl-H3K9 substrate peptide bind.
As shown in Figure 4, substrate peptide andNAD+both locate
in the interspace between zinc2+ binding domain and Ross-
mann fold domain. Those residues including Phe70, Arg71,
Gln140, Asn141, and Asp143, are very important for NAD+
binding (Figure 4). The Gln140 and Asn141 hold the bind-
ing of NAD+ ribose part, and Asp143 directly interacts with
nicotinamide part. More interestingly, the flexible residue
Phe70 plays a crucial role in keep NAD+ binding/unbinding,
like a switch residue (Figure 4). For substrate peptide bind-
ing, the important residues include His158, Phe223, Try102
and Arg105 (Figure 4). As described above, Tyr102 and
Arg105 are the unique residues for SIRT5, which form hy-
drogen-bonding and ionic-bonding interactions with the car-
boxyl of succinyl-lysine substrate. Besides, we observed that
the succinyl moiety of substrate peptide is positioned to make
direct interactions with ribose motif of NAD+.
SIRT5 INHIBITORS
SIRT5 is known to be involved in cellular metabolism and
metabolic energy homeostasis  by  its various protein substr-
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Figure 4   An example of the succinyl-K9 peptide-NAD+ ternary crystal structure (PDB code: 3RIY).
strates. The possibilities of targeting SIRT5 are beginning to
be more extensively investigated with aim of providing new
strategies for the treatment of related diseases, since SIRT5
was demonstrated to be activation/over-expression in several
human diseases (i.e. cancer). For example, an integrated ge-
nomic analyses of ovarian carcinoma revealed that region en-
compassing the SIRT5 locus was amplified 30% in ovarian
carcinoma (Network, 2011). Very recently, Lu et al. found
that SIRT5 is over-expressed in advanced non-small cell lung
cancer (NSCLC), and knock-down of SIRT5 could repress
the growth rate of NSCLC cell lines (Lu et al., 2014). Lutz
and his colleagues revealed that the expression of SIRT5 was
increased during the progression of Alzheimer’s disease in
contrast to SIRT1 and SIRT (Lutz et al., 2014). Glorioso et al.
found that SIRT5 might be an important risk factor contribut-
ing to mitochondrial dysfunction-related diseases including
Parkinson’s disease through accelerating molecular aging of
disease-related genes (Glorioso et al., 2011). Discovery of
SIRT5 inhibitors is likely to be an attractive area for treatment
of associated diseases. The reported peptide and small-mole-
cule inhibitors of SIRT5 are hence summarized in following
section.
Peptide inhibitors
Peptide inhibitors usually can be used as not only chemical
probes for molecular mechanism research but also good
starting points for small-molecule inhibitor design. Inspired
by the fact that thioacetyl peptides can inhibit the deacetylase
activities of sirtuins via forming a stable covalent interme-
diate, He and co-workers (He et al., 2012) synthesized the
first SIRT5-specific inhibitor, namely histone H3K9 thiosuc-
cinyl peptide (H3K9TSu, Figure 5), which is a competitive
inhibitor with an IC50 value of 5 μmol L–1. Subsequent
structure-activity relationship (SAR) study showed that
the peptide inhibitors with a thiosuccinyl-lysine residue at
the C-terminus or N-terminus were less potent than that
in the middle, and the longer thiosuccinyl peptide seems
to have better inhibitory activity against SIRT5. Another
study by Roessler et al. investigated SAR of lysine side
chain of SIRT5 substrate carbamoyl phosphate synthetase
(CPS1), and eventually identified several potent peptide
inhibitors 1–4 (Figure 5) (Roessler et al., 2014), of Ki values
are 17.2±1.31, 38.1±0.63, 4.3±0.32, and 10.6±0.66 μmol
L–1, respectively. Very recently, Zang et al. identified a
selective, potent SIRT5 inhibitory warhead, namely Nɛ-car-
boxyethyl-thiourea-lysine, and compound 5 harboring this
warhead has an IC50 value of 5.0 μmol L–1 against SIRT5
(Figure 5) (Zang et al., 2015). More interestingly, peptide
inhibitors containing this warhead seem to circumvent the
cytotoxicity problem associated with the inhibitors bearing
the Nɛ-thioacyl-lysines.
Small molecule inhibitors
Given the fact that peptide inhibitors generally suffered from
limited pharmacological relevance due to their size, limited
biostability and poormembrane permeability, it is desirable to
develop small-molecule SIRT5 inhibitors for characterizing
the physiological function and therapeutic potential. Suramin
is one of the very few known pharmacological SIRT5 small-
molecule inhibitors, which inhibits SIRT5 non-specifically at
submicromolar level by blocking substrate andNAD+binding
(Figure 6) (Gertz and Steegborn, 2010; Schuetz et al., 2007).
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Figure 5   The known peptide inhibitors of SIRT5.
Figure 6   The known small-molecule inhibitors of SIRT5.
Maurer et al. using their own established method tested sev-
eral known SIRT1-3 small-molecule inhibitors and co-prod-
ucts of the reaction of deacetylation and deacylation, nicoti-
namide against SIRT5, and found that sirtinol, cambinol and
nicotinamide (Figure 6) can inhibit SIRT5 at submicromolar
level (Maurer et al., 2012). Similarly, Suenkel’s group has
found that GW5074 (Figure 6) has considerable inhibitory
activity to SIRT5’s desuccinylation activity (85% inhibitory
activity at 100 μmol L–1), but it has weaker effects to SIRT5
deacetylation (Suenkel et al., 2013). Different from above
studies, Maurer et al. identified thiobarbiturate-containing
compound 9 and compound 10 (Figure 6) as new inhibitors
by direct screening, which have low μmol L–1 potency against
SIRT5 (Maurer et al., 2012). These inhibitors should be good
starting points to develop new SIRT5 inhibitors.
CLUES AND METHODS FOR THE DESIGN OF
NEW SIRT5 INHIBITORS
As mentioned above, SIRT5 is a potential drug target, but
few SIRT5 inhibitors have been reported so far. It is presently
desirable to discover new SIRT5 inhibitors for molecular
mechanism research and drug discovery. Some clues ex-
tracted from available crystal structures and inhibitors of
SIRT5 as well as those of other sirtuins, and practical com-
puter-aided drug design (CADD) methods given in following
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section should be useful in further efforts to develop new
SIRT5 inhibitors.
The NAD+ binding site and substrate binding site are
currently two main binding pockets for SIRT5 inhibitors.
For NAD+binding site, those attempts including identifying
NAD+ analogues and competitive inhibitors could be an
effective strategy to inhibit SIRT5. However, due to that
a large number of human enzymes use NAD+ as a co-sub-
strate, the inhibitors against NAD+ binding site may result in
concerns of their target selectivity. In contrast, to discover
selective SIRT5 inhibitors via targeting substrate binding site
is likely to be a recommended strategy since some specific
residues (i.e. Tyr102, Arg105, and Ala86) form a relatively
large, specific substrate binding pocket (for details please see
structure characteristics of SIRT5).
According to available substrate-SIRT5 complex struc-
tures, three important features for substrate binding con-
cluded here could be useful for designing inhibitors targeting
substrate binding pocket. First, two specific non-hydropho-
bic residues, Arg105 and Tyr102, in the deep end of substrate
binding pocket interact with the succinyl-lysine group of
substrate via hydrogen-bonding and electrostatic interac-
tions (Figure 4), indicating that negatively charged groups
(i.e. carboxyl and tetrazole) or polar chemical groups (i.e.
sulfonamide and isoxazol-3-ol) could be preferred chemical
moieties to occupy this kind of pocket. Second, Phe223 in
loop S is likely to be a gate keeper to restrict large fragments
to go into the deep end of substrate binding pocket, suggest-
ing that it is desirable to design some rigid, linear chemical
moieties or small aromatic rings as linkage scaffolds with
key pharmacophore features. Third, three hydrophobic
residues including Leu227, Val254, Phe223 form a trian-
gle-shaped entrance for substrate binding, which suggests
that small-molecule compounds with similar triangle shapes
might perfectly fit with the substrate binding site. Besides,
some clues also could be obtained from SIRT5’s neighbor
family members, even though they have structural differ-
ences. For example, Rumpf et al. recently found a new
binding pocket for SIRT2 induced by a selective inhibitor,
termed SirReal2 (Rumpf et al., 2015). This study might
inspire people to search novel SIRT5 inhibitors targeting
other possible unexploited binding pockets.
Currently, a number of well-established CADD methods
(Ekins et al., 2007; Li et al., 2015c) could be very useful
in designing new SIRT5-specific inhibitors. For example,
according to available substrate-SIRT5 crystal structures,
three dimensional (3D) shape-based methods such as ROCS,
ShaEP and Phase Shape would be effective tools to identify
small-molecule compounds having similar shape with SIRT5
substrate. Pharmacophore-based methods (Yang et al., 2012;
Yang, 2010) can be used to generate a reasonable pharma-
cophore model from substrate-SIRT5 structures to search
for potential inhibitors. Molecular docking and molecular
dynamics methods also are very useful in lead discovery and
lead optimization. Recently, some combined hierarchical in
silico methods were established, which could avoid inherent
shortcomings of each individual method and capitalize on
their mutual strengths (Li et al., 2011; Ren et al., 2011). A
hierarchical virtual screening method described in following
might be a useful method to identify new SIRT5 inhibitors.
The first step is to establish a carboxyl/carboxyl isostere
focused chemical library for SIRT5 since carboxyl/carboxyl
isostere groups may form interactions with the specific
residues Arg105 and Tyr102. The second step is to use
molecular docking to search possible binding poses for
the established focused chemical library. The third step is
to use interaction fingerprints-based methods or pharma-
cophore-based to filter the docking poses (de Graaf et al.,
2011; Muthas et al., 2008). The final step is to use rescoring
methods for example molecular mechanics Poisson-Boltz-
mann surface area (MM-PBSA) (Suri and Naik, 2015) and
ID-Score (Li et al., 2013) to predict the binding affinity for
providing information to help select potential hit compounds.
The use of these multiple, complementary methods could
increase the success rate of identifying new SIRT5 inhibitors.
In addition to above described methods, structure-based or
pharmacophore-based de novo design methods (Schneider
and Fechner, 2005; Talamas et al., 2013) as well as scaffold
hopping or substitute modification methods (Li et al., 2015b;
Mauser and Guba, 2008) are worth to use because these
methods might be able to discover novel SIRT5 inhibitors
with novel chemical scaffolds.
SUMMARY
SIRT5 is an attractive enzyme for mechanism research
since it not only has deacetylase activity but also has strong
demalonylase, desuccinylase and deglutarylase activities.
SIRT5 is also considered as a potential molecular target for
treatment of several human diseases. In this review, we
summarized the structural characteristics of SIRT5 and its
structural differences to other sirtuins, and highlighted the
detailed, specific structural binding of SIRT5 substrates. In
addition, we gave a summary of currently known peptide and
small-molecule SIRT5 inhibitors. Moreover, we extracted
some clues from current available information and gave
some feasible, practical in silicomethods for SIRT5 inhibitor
design. We hope this review can help people understand
SIRT5 structure characteristics and provide useful infor-
mation for further efforts to develop new SIRT5 inhibitors
for related molecular mechanism research as well as drug
discovery & development.
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